Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Gains from Investment Securities (2016 - 2025)

Mimedx's Gains from Investment Securities history spans 12 years, with the latest figure at $3.0 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 1373.76% year-over-year to $3.0 million; the TTM value through Jun 2025 reached $5.6 million, up 32888.24%, while the annual FY2025 figure was $3.1 million, 17.38% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was $3.0 million at Mimedx, up from $7000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.2 million in Q1 2021 and bottomed at -$3.2 million in Q2 2021.
  • The 4-year median for Gains from Investment Securities is $202000.0 (2024), against an average of $527153.8.
  • The largest annual shift saw Gains from Investment Securities plummeted 319500.0% in 2021 before it soared 1373.76% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $274000.0 in 2021, then surged by 323.72% to $1.2 million in 2022, then crashed by 97.42% to $30000.0 in 2024, then soared by 9823.33% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Gains from Investment Securities are $3.0 million (Q2 2025), $7000.0 (Q1 2025), and $30000.0 (Q4 2024).